GlassScriptPhysician profile
Kruti Patel
NPI 1477948172
$6,029.70
in general payments reported to CMS, 2019-2025
34 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.45 · 2020: $147 · 2021: $373 · 2022: $1,101 · 2023: $1,395 · 2024: $1,884 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,321.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,907.23 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $565.32 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $466.15 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.20 | 2022-2025 | Xifaxan, Trulance, Cycloset |
| Madrigal Pharmaceuticals | $237.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $224.03 | 2024 | Livdelzi, Vemlidy |
| Genzyme Corporation | $215.29 | 2022-2025 | |
| Ardelyx, INC. | $209.27 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $200.21 | 2023-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $196.96 | 2021-2025 | Pillcam, Gi Genius |
| Janssen Biotech, INC. | $190.88 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Janssen Scientific Affairs, LLC | $180.49 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $175.56 | 2021-2025 | Ocaliva |
| Evoke Pharma, INC. | $119.49 | 2022-2025 | Gimoti |
| Vivus LLC | $99.64 | 2023-2024 | Qsymia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $88.02 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $86.74 | 2022-2024 | Emblem Mri S-Icd |
| Nestle Healthcare Nutrition INC. | $84.62 | 2022-2023 | |
| Celgene Corporation | $71.42 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $60.62 | 2021-2025 | Suflave |
| Aimmune Therapeutics, INC. | $54.75 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $48.22 | 2025 | Iqirvo |
| Pfizer INC. | $45.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $41.52 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $31.16 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $25.94 | 2024 | Rapide Balloons |
| Ironwood Pharmaceuticals, INC | $19.22 | 2023 | Linzess |
| Allergan, INC. | $16.05 | 2020 | |
| Enterra Medical, INC. | $15.85 | 2024 | |
| Myriad Genetic Laboratories, INC. | $15.67 | 2023 | Myrisk |
| Celltrion USA INC. | $14.82 | 2025 | Vegzelma |
| Tolmar, INC. | $14.14 | 2024 | |
| Redhill Biopharma INC. | $13.71 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kruti Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.